Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Stoke Therapeutics's pe ratio was 45.3× on Jan 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 45.3× | −2.1 |
| 2025 | Dec 31, 2025 | 47.4× | – |
See a number that looks wrong?